Shares of Pro Medicus Ltd (ASX: PME) plummeted 5.86% in Friday's trading session, as growth stocks continue to face selling pressure in the market. The sharp decline comes amid a broader correction affecting high-flying growth names across various sectors.
The selloff in Pro Medicus aligns with a trend observed in other quality growth stocks, which have shed 10% to 30% in recent weeks. Market experts suggest that while such corrections can be unsettling for investors, it's crucial to stay focused on company fundamentals rather than making emotional decisions based solely on price movements.
Despite the current downturn, some investors see potential opportunities in Pro Medicus. Adam Dawes, Senior Investment Adviser at Shaw & Partners, noted, "We took advantage of weakness in Pro Medicus – longer term, the global imaging opportunity remains intact." This perspective highlights the importance of maintaining a long-term view on high-quality growth companies, even during periods of market volatility.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。